Filing Overview
Registrant: GX Acquisition Corp., not Celularity Inc. The Form 8-K was filed May 24, 2019, reporting events occurring primarily on May 20 and May 23, 2019. The filing concerns the company’s initial public offering and related financing transactions; it does not report operating results for Celularity Inc.
Key Financial and Capitalization Matters
- IPO: 28,750,000 units were sold at $10.00 per unit, generating gross proceeds of $287.5 million. The issuance included the underwriters’ full 3,750,000-unit over-allotment.
- Each unit consisted of one Class A common share and one-half of one redeemable warrant. Each whole warrant is exercisable for one Class A share at $11.50 per share.
- Private placement: The sponsor purchased 7,000,000 warrants at $1.00 per warrant, generating gross proceeds of $7.0 million.
- Trust account: $287.5 million was deposited into a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer & Trust Company as trustee. The amount comprised $280.5 million of IPO proceeds and $7.0 million from the private placement.
- The filing does not provide operating revenue, net income, cash flow from operations, margins, or debt balances for the reported period.
Material Changes and Transactions
- The company completed its IPO and the related private placement of warrants.
- The company entered into underwriting, warrant, sponsor, trust, registration rights, administrative support, and related agreements.
- The company filed an Amended and Restated Certificate of Incorporation effective May 20, 2019.
- The securities were listed on Nasdaq under the symbols GXGXU, GXGX, and GXGXW.
Outlook, Restrictions, and Risks
- The trust funds are generally restricted until the earliest of completion of an initial business combination, certain approved stockholder redemptions, or redemption of public shares if no business combination is completed within 24 months after the IPO closing.
- Interest earned on the trust funds may be released for taxes, subject to the stated limitation of up to $100,000 of interest for dissolution expenses.
- The filing does not identify a target business, provide business-combination guidance, or include management forecasts.
- Private placement warrants are generally nontransferable until 30 days after completion of the initial business combination and are not redeemable while held by the sponsor or permitted transferees.
- Completion of a business combination within the 24-month period is a key contingency; failure to do so would generally trigger redemption of the public shares, subject to applicable law.
Investor Verification Points
- Verify the correct issuer: the supplied filing is for GX Acquisition Corp., while the request identifies Celularity Inc.
- Review the warrant agreement for exercise, redemption, and adjustment provisions.
- Confirm the terms governing trust-account releases and public-share redemptions.
- Review the sponsor letter, private placement agreement, registration rights agreement, and amended charter for dilution, lock-up, governance, and business-combination provisions.
- Confirm whether a subsequent filing identifies the eventual business combination or any changes to the 24-month liquidation framework.